Assessment of background levels of autoantibodies as a prognostic marker for severe SARS-CoV-2 infection
Open Access
- 3 May 2022
- journal article
- Published by Aboutscience Srl in Journal of Circulating Biomarkers
- Vol. 11, 24-27
- https://doi.org/10.33393/jcb.2022.2337
Abstract
Background: Patients with more severe forms of SARS-CoV-2 exhibit activation of immunological cascades. Participants (current or ex-smokers with at least 20 years pack history) in a trial (Early Diagnosis of Lung Cancer, Scotland [ECLS]) of autoantibody detection to predict lung cancer risk had seven autoantibodies measured 5 years before the pandemic. This study compared the response to Covid infection in study participants who tested positive and negative to antibodies to tumour-associated antigens: p53, NY-ESO-1, CAGE, GBU4-5, HuD, MAGE A4 and SOX2. Methods: Autoantibody data from the ECLS study was deterministically linked to the EAVE II database, a national, real-time prospective cohort using Scotland’s health data infrastructure, to describe the epidemiology of SARS-CoV-2 infection, patterns of healthcare use and outcomes. The strength of associations was explored using a network algorithm for exact contingency table significance testing by permutation. Results: There were no significant differences discerned between SARS-CoV-2 test results and EarlyCDT-Lung test results (p = 0.734). An additional analysis of intensive care unit (ICU) admissions detected no significant differences between those who tested positive and negative. Subgroup analyses showed no difference in COVID-19 positivity or death rates amongst those diagnosed with chronic obstructive pulmonary disease (COPD) with positive and negative EarlyCDT results. Conclusions: This hypothesis-generating study demonstrated no clinically valuable or statistically significant associations between EarlyCDT positivity in 2013-15 and the likelihood of SARS-CoV-2 positivity in 2020, ICU admission or death in all participants (current or ex-smokers with at least 20 years pack history) or in those with COPD or lung cancer.Keywords
This publication has 27 references indexed in Scilit:
- Multicenter analysis of clinical characteristics and outcomes in patients with COVID-19 who develop liver injuryJournal of Hepatology, 2020
- Serum and blood based biomarkers for lung cancer screening: a systematic reviewBMC Cancer, 2018
- Detection in blood of autoantibodies to tumour antigens as a case-finding method in lung cancer using the EarlyCDT®-Lung Test (ECLS): study protocol for a randomized controlled trialBMC Cancer, 2017
- EarlyCDT-Lung: An Immunobiomarker Test as an Aid to Early Detection of Lung CancerCancer Prevention Research, 2011
- Technical validation of an autoantibody test for lung cancerAnnals of Oncology, 2010
- Profiling tumor-associated antibodies for early detection of non-small cell lung cancer.2006
- Profiling Tumor-Associated Antibodies for Early Detection of Non-small Cell Lung CancerJournal of Thoracic Oncology, 2006
- The Sentinel Within: Exploiting the Immune System for Cancer BiomarkersJournal of Proteome Research, 2005
- Phases of Biomarker Development for Early Detection of CancerJNCI Journal of the National Cancer Institute, 2001
- The Scottish Record Linkage System.1993